A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results

Journal of Clinical Microbiology

Volumn 53, Issue 1, 2015, Pages 52-59

  Schiffman, M ^a   Burk, R D ^b   Boyle, S ^c   Raine Bennett, T ^d   Katki, H A ^a   Gage, J C ^a   Wentzensen, N ^a   Kornegay, J R ^c   Aldrich, C ^c   Tam, T ^c   Erlich, H ^c   Apple, R ^c   Befano, B ^e   Castle, P E ^f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c ROCHE MOLECULAR SYSTEMS   (United States)

^d KAISER PERMANENTE   (United States)

^e INFORMATION MANAGEMENT SERVICES INC   (United States)

^f Global Coalition Against Cervical Cancer   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SCREENING; CASE CONTROL STUDY; CONTROLLED STUDY; CYTOLOGY; FEMALE; FOLLOW UP; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 68; MAJOR CLINICAL STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; SAMPLING; UTERINE CERVIX CARCINOMA IN SITU; VERY ELDERLY; WART VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLASSIFICATION; COLPOSCOPY; COMPLICATION; EARLY DIAGNOSIS; GENETICS; INCIDENCE; MIDDLE AGED; MOLECULAR TYPING; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; UTERINE CERVIX; VIROLOGY;

HUMAN PAPILLOMAVIRUS;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; COLPOSCOPY; EARLY DETECTION OF CANCER; FEMALE; GENOTYPE; HUMANS; INCIDENCE; MIDDLE AGED; MOLECULAR TYPING; PAPANICOLAOU TEST; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84919473281     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02116-14     Document Type: Article

References (23)

1. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain JM, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS, Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER. 2012. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis 16:175-204. http://dx.doi.org/10.1097/LGT.0b013e31824ca9d5.
2. Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ. 2009. Validation of high-risk HPV tests for primary cervical screening. J Clin Virol 46(Suppl 3):S1-S4. http://dx.doi.org/10.1016/S1386-6532(09)00540-X.
3. Castle PE, Stoler MH, Wright TC, Jr, Sharma A, Wright TL, Behrens CM. 2011. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 12:880-890. http://dx.doi.org/10.1016/S1470-2045(11)70188-7.
4. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJLM, International HPV Screening Working Group. 2013. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 383: 524-532. http://dx.doi.org/10.1016/S0140-6736(13)62218-7.
5. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, Kane S, Desai S, Keskar VR, Rajeshwarkar R, Panse N, Dinshaw KA. 2009. HPV screening for cervical cancer in rural India. N Engl J Med 360:1385-1394. http://dx.doi.org/10.1056/NEJMoa0808516.
6. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Hesselink AT, Rozendaal L, Heideman DA, Verheijen RH, Bulk S, Verweij WM, Snijders PJ, Meijer CJ. 2012. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 130:602-610. http://dx.doi.org/10.1002/ijc.26056.
7. Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC, Jr, Cuzick J, Athena HPV Study Group. 2013. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol 208:184.e1-184.e11. http://dx.doi.org/10.1016/j.ajog.2012.11.020.
8. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK. 2013. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis 17:S56-S63. http://dx.doi.org/10.1097/LGT.0b013e318285437b.
9. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK. 2013. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis 17:S28-S35. http://dx.doi.org/10.1097/LGT.0b013e318285423c.
10. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, Solomon D, Wentzensen N, Lawson HW. 2013. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 17:S1-S27. http://dx.doi.org/10.1097/LGT.0b013e318287d329.
11. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, Castle PE. 2011. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 12:663- 672. http://dx.doi.org/10.1016/S1470-2045(11)70145-0. (Erratum, 12:722, 2011.)
12. Chen HC, Schiffman M, Lin CY, Pan MH, You SL, Chuang LC, Hsieh CY, Liaw KL, Hsing AW, Chen CJ, CBCSP-HPV Study Group. 2011. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst 103:1387-1396. http://dx.doi.org/10.1093/jnci/djr283.
13. Schiffman M, Wentzensen N. 2013. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev 22:553-560. http://dx.doi.org/10.1158/1055-9965.EPI-12-1406.
14. Dinkelspiel H, Fetterman B, Poitras N, Kinney W, Cox JT, Lorey T, Castle PE. 2014. Cervical cancer rates after the transition from annual Pap to 3-year HPV and Pap. J Low Genit Tract Dis 18:57-60. http://dx.doi.org/10.1097/LGT.0b013e31829325c3.
15. Castle PE, Shaber R, LaMere BJ, Kinney W, Fetterma B, Poitras N, Lorey T, Schiffman M, Dunne A, Ostolaza JM, McKinney S, Burk RD. 2011. Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California. Cancer Epidemiol Biomarkers Prev 20:946-953. http://dx.doi.org/10.1158/1055-9965.EPI-10-1267.
16. Castle PE, Stoler MH, Solomon D, Schiffman M. 2007. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol 127:805-815. http://dx.doi.org/10.1309/PT3PNC1QL2F4D2VL.
17. Gage JC, Sadorra M, Lamere BJ, Kail R, Aldrich C, Kinney W, Fetterman B, Lorey T, Schiffman M, Castle PE, PaP Cohort Study Group. 2012. Comparison of the Cobas human papillomavirus (HPV) test with the Hybrid Capture 2 and Linear Array HPV DNA tests. J Clin Microbiol 50:61-65. http://dx.doi.org/10.1128/JCM.05989-11.
18. Castle PE, Schiffman M, Gravitt PE, Kendall H, Fishman S, Dong H, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Lorincz A, Schussler JE, Burk RD. 2002. Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol 68:417-423. http://dx.doi.org/10.1002/jmv.10220.
19. Arbyn M, Roelens J, Cuschieri K, Cuzick J, Szarewski A, Ratnam S, Reuschenbach M, Belinson S, Belinson JL, Monsonego J. 2013. The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer 132:101-108. http://dx.doi.org/10.1002/ijc.27636.
20. Cuzick J, Ho L, Terry G, Kleeman M, Giddings M, Austin J, Cadman L, Ashdown-Barr L, Costa MJ, Szarewski A. 2014. Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions. J Clin Virol 60:44-49. http://dx.doi.org/10.1016/j.jcv.2014.02.002.
21. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, Clifford GM. 2012. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer http://dx.doi.org/10.1002/ijc.27485.
22. Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA, Allen RA, Zhang R, Sherman ME, Wacholder S, Walker J, Wang SS. 2009. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer 125:2151-2158. http://dx.doi.org/10.1002/ijc.24528.
23. Kjaer SK, Frederiksen K, Munk C, Iftner T. 2010. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 102:1478-1488. http://dx.doi.org/10.1093/jnci/djq356.